SCYNEXIS, Inc. (NASDAQ:SCYX)’s share price was up 5.3% during trading on Tuesday . The stock traded as high as $2.27 and last traded at $2.17. Approximately 737,700 shares changed hands during mid-day trading, an increase of 118% from the average daily volume of 337,666 shares. The stock had previously closed at $2.06.
Several equities analysts have recently commented on SCYX shares. ValuEngine downgraded SCYNEXIS from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Guggenheim started coverage on SCYNEXIS in a research report on Tuesday, October 24th. They issued a “buy” rating and a $6.00 target price on the stock. Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, August 29th. Finally, Roth Capital set a $9.00 price target on SCYNEXIS and gave the company a “buy” rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. SCYNEXIS currently has a consensus rating of “Buy” and an average price target of $8.43.
The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30.
TRADEMARK VIOLATION NOTICE: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://sportsperspectives.com/2017/12/05/scynexis-scyx-trading-up-5-3.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.